Global leaders pledge US$2.6 billion to eradicate polio at the Reaching the Last Mile Forum in Abu Dhabi - World Health Organization

Global leaders pledge US$2.6 billion to eradicate polio at the Reaching the Last Mile Forum in Abu Dhabi - World Health Organization

Global leaders pledge US$2.6 billion to eradicate polio at the Reaching the Last Mile Forum in Abu Dhabi - World Health Organization

Posted: 19 Nov 2019 04:05 AM PST

Today, global leaders convened at the Reaching the Last Mile (RLM) Forum in Abu Dhabi to affirm their commitment to eradicate polio and pledge US$2.6 billion as part of the first phase of the funding needed to implement the Global Polio Eradication Initiative's Polio Endgame Strategy 2019-2023.

This pledging event comes on the heels of a major announcement last month that the world has eradicated two of the three wild poliovirus strains, leaving only wild poliovirus type 1 (WPV1) still in circulation. Additionally, Nigeria – the last country in Africa to have cases of wild polio – has not seen wild polio since 2016 and the entire WHO African region could be certified wild polio-free in 2020. Thanks to the dedicated efforts of health workers, governments, donors and partners, wild polio only circulates in two countries: Pakistan and Afghanistan.

"From supporting one of the world's largest health workforces, to reaching every last child with vaccines, the Global Polio Eradication Initiative is not only moving us closer to a polio-free world, it's also building essential health infrastructure to address a range of other health needs," said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization and Chair of the Polio Oversight Board. "We are grateful for the generous pledges made today and thank governments, donors and partners for standing with us. In particular, I would like to thank His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi for hosting the GPEI pledging moment and for his long-term support for polio eradication."

The commitments announced today come at a critical time for the polio eradication effort. Barriers to reaching every child – including inconsistent campaign quality, insecurity, conflict, massive mobile populations, and, in some instances, parental refusal to the vaccine – have led to ongoing transmission of the wild poliovirus in Pakistan and Afghanistan. Further, low immunity to the virus in parts of Africa and Asia where not all children are vaccinated has sparked outbreaks of a rare form of the virus. To surmount these obstacles and protect 450 million children from polio every year, governments and donors announced significant new financial commitments toward the $3.27 billion needed to support the Polio Endgame Strategy.

Pledges are from a diverse array of donors, including: US$160 million from the host of the pledging moment His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi; countries, including US$215.92 million from the United States, US$160 million from the Islamic Republic of Pakistan, US$105.05 million from Germany, US$84.17 million from the Federal Government of Nigeria, US$10.83 million from Norway, US$10.29 million from Australia, US$7.4 million from Japan, US$2.22 million from Luxembourg, US$1.34 million from New Zealand, US$116,000 from Spain, and US$10,000 from Liechtenstein; GPEI partners, including US$1.08 billion from the Bill & Melinda Gates Foundation and US$150 million from Rotary International; philanthropic organizations, including US$50 million from Bloomberg Philanthropies, US$25 million from Dalio Philanthropies, US$15 million from the Tahir Foundation, US$6.4 million from the United Nations Foundation, US$2 million from Alwaleed Philanthropies, US$1 million from the Charina Endowment Fund, and US$1 million from Ningxia Yanbao Charity Foundation; and the private sector, including US$1 million from Ahmed Al Abdulla Group, US$1 million from Al Ansari Exchange, and US$340,000 from Kasta Technologies. Earlier this month, the United Kingdom announced it would contribute up to US$514.8 million to the GPEI.

"We are proud to host the GPEI pledging moment in Abu Dhabi and thank all the attendees for their continued commitment to the eradication of polio," said Her Excellency Reem Al Hashimy, UAE Cabinet Member and Minister of State for International Cooperation. "Since launching in 2014, the Emirates Polio Campaign has delivered more than 430 million polio vaccines in some of the most remote areas of Pakistan.  We remain firm in our mission to reach every last child and believe together we can consign polio to the pages of history."

In addition to overcoming barriers to reach every child, this funding will ensure the resources and infrastructure built by the GPEI can support other health needs today and in the future. Polio workers deliver Vitamin A supplements, provide other vaccines like those for measles and yellow fever, counsel new mothers on breastfeeding, and strengthen disease surveillance systems to anticipate and respond to outbreaks. As part of its commitment to advance gender equality and women's empowerment, the GPEI is also working to ensure equal participation of women at all levels of the programme.

The future of polio eradication hinges on support and engagement at all levels of the programme – from individuals to communities to local and national governments to donors. If the strategies needed to reach and vaccinate children are fully implemented and funded, we are confident that we can deliver a world where no child lives in fear of polio.

UNICEF-WHO Philippines: Polio Outbreak Situation Report #9 (26 November 2019) - Philippines - ReliefWeb

Posted: 26 Nov 2019 05:31 AM PST

Highlights

Since 19 November 2019:

  • Three new cases with circulating Vaccine Derived Polio Virus type 2 (cVDPV2) from Cotabato City, Midasayap (North Cotabato) and Talayang (Maguindanao).

  • First human case confirmed with VDPV type 1 from Basilan, an island province part of the Bangsamoro Autonomous Region in Muslim Mindanao (BARMM). Case is not genetically linked to the environmental samples tested positive in Manila, indicating new emergence.

  • Four healthy children from Maguindanao were found with cVDPV2, all linked to previously detected cVDPV2 from Mindanao.

  • Five new environmental samples positive for cVDPV2 from several sites in Manila and 2 new environmental samples positive for cVDPV1 from two sites in Manila.

  • Start of synchronized polio vaccination campaign on 25 November until 7 December targeting 4.4 million children under 5 in National Capital Region (NCR) and 6 regions in Mindanao.

  • Current polio outbreak resulting from persistently low routine immunization coverage, and poor sanitation and hygiene.

  • Philippines is affected by both cVDPV1 and cVDPV2. cVDPV is considered a public health emergency of international concern (PHEIC).

Current Situation

First human case tested positive for VDPV1 from the island province of Basilan in BARMM is a 9-year female with no history of previous vaccination against polio. The virus is 3.3% nucleotide divergence from Sabin1 and not linked to the environmental samples tested positive in Manila.
Three additional positive cVDPV2 cases were found from Cotabato City, Midasayap (North Cotabato) and Talayang (Maguindanao). There is frequent travel within the BARMM provinces and to other parts of Mindanao as well all the way to Manila. The case in Cotabato City had recent travel to Talayang where the case occurred. Both Midasyap and Talayang are located within an hour of Datu Piang, where an earlier cVPDV2 case was found, which is the cultural hub of Maguindanao province.
Furthermore, 4 positive cVDPV2 samples from 4 healthy children were taken in Datu Piang, Maguindanao province, confirming there is circulation of VDPV2 in the area. The samples were taken before the outbreak response immunization activity in Datu Piang, Datu Paglas and Lambayong on 4-8 November.
All samples were tested by the National Polio Laboratory at the Research Institute for Tropical Medicine (RITM), whereas sequencing and genetic analysis is done at the NIID in Japan and additional genetic characterization provided by the United States Centers for Disease Control and Prevention (CDC).
The next round of the synchronized polio vaccination campaign started on 25 November and will last until 7 December targeting 4.4 million children under 5 in NCR and 6 regions in Mindanao.

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

Image
causes of precapillary pulmonary hypertension :: Article Creator Long-term Oxygen Therapy Improves Exercise Capacity In PH Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42 meters (about 138 feet) over the distances walked at start of the study, "Long-term oxygen therapy in precapillary pulmonary hypertension — SOPHA study," which was published in Scientific Reports. PH is marked by high blood pressure in the pulmonary arteries, the blood vessels that transport blood from the heart to the lungs. Precapillary PH includes PAH, where blood pressure increases due to the narrowing of pulmonary arteries, along with CTEPH, a rare form of p...
Read more